- Home
- DMAC vs CIO Comparison
DMAC vs CIO Comparison
Compare DMAC & CIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- CIO
- Stock Information
- Founded
- DMAC 2000
- CIO 2013
- Country
- DMAC United States
- CIO Canada
- Employees
- DMAC N/A
- CIO N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- CIO Real Estate Investment Trusts
- Sector
- DMAC Health Care
- CIO Real Estate
- Exchange
- DMAC Nasdaq
- CIO Nasdaq
- Market Cap
- DMAC 178.0M
- CIO 212.3M
- IPO Year
- DMAC N/A
- CIO 2014
- Fundamental
- Price
- DMAC $3.63
- CIO $5.55
- Analyst Decision
- DMAC Strong Buy
- CIO
- Analyst Count
- DMAC 2
- CIO 0
- Target Price
- DMAC $8.00
- CIO N/A
- AVG Volume (30 Days)
- DMAC 110.0K
- CIO 130.2K
- Earning Date
- DMAC 08-06-2025
- CIO 07-31-2025
- Dividend Yield
- DMAC N/A
- CIO 7.35%
- EPS Growth
- DMAC N/A
- CIO N/A
- EPS
- DMAC N/A
- CIO N/A
- Revenue
- DMAC N/A
- CIO $168,891,000.00
- Revenue This Year
- DMAC N/A
- CIO $1.13
- Revenue Next Year
- DMAC N/A
- CIO $3.73
- P/E Ratio
- DMAC N/A
- CIO N/A
- Revenue Growth
- DMAC N/A
- CIO N/A
- 52 Week Low
- DMAC $2.14
- CIO $4.19
- 52 Week High
- DMAC $6.82
- CIO $6.50
- Technical
- Relative Strength Index (RSI)
- DMAC 46.56
- CIO 74.04
- Support Level
- DMAC $4.02
- CIO $5.32
- Resistance Level
- DMAC $4.17
- CIO $5.41
- Average True Range (ATR)
- DMAC 0.25
- CIO 0.14
- MACD
- DMAC -0.04
- CIO 0.04
- Stochastic Oscillator
- DMAC 37.89
- CIO 94.16
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About CIO City Office REIT Inc.
City Office REIT Inc is a real estate investment trust. It is focused on acquiring, owning, and operating high-quality office properties located predominantly in Sun Belt markets. The principal objective of the company is to provide attractive risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. Its properties includes: Pima Center, SanTan, Park Tower, Intellicenter, Intellicenter, Denver Tech, Canyon Park, AmberGlen and many. The company own these office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, Raleigh, San Diego, Seattle, and Tampa.